Browsing Tag
AbbVie Inc.
8 posts
AbbVie commits $380m to expand US drug manufacturing as supply chain control becomes strategic
AbbVie is investing $380 million to expand US drug manufacturing. Find out how this reshapes supply chains, margins, and long-term pharma strategy.
Can fixed-duration oral therapy finally replace indefinite CLL treatment? AstraZeneca’s FDA win explains why
FDA approval of AstraZeneca’s CALQUENCE plus venetoclax introduces a fixed-duration oral option for frontline CLL. Find out why this matters for patients and investors.
AbbVie Inc. (NYSE: ABBV) wins FDA approval for Venclexta and acalabrutinib in first-line chronic lymphocytic leukemia
AbbVie Inc. secures FDA approval for Venclexta plus acalabrutinib in first-line CLL. Find out why this decision matters for patients, payers, and investors.
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
Is bretisilocin the Cymbalta of psychedelic‑inspired psychiatry? What AbbVie’s $1.2 bn bet reveals
AbbVie’s $1.2 B deal for bretisilocin could signal the next era of antidepressants. Could this short‑acting compound become the Cymbalta of psychedelic‑inspired psychiatry?
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.
Global-E, Forge Global, Cellebrite lead top U.S. stock losers as market caution grows
Discover why top U.S. stocks like GLBE, FRGE, CLBT, and ABBV fell on May 14, 2025. Full breakdown of today's biggest stock losers with macro context.
Alembic Pharmaceuticals wins big with FDA approval for new allergy eye drops
In a major development that could impact the over-the-counter pharmaceutical market, Alembic Pharmaceuticals Limited has received final approval…